North America Bioreactors Market size exceeded USD 3.2 billion in 2021 and is projected to register 13.5% CAGR from 2022 to 2028.

Scalability of operations, improved flexibility, and quality of bioreactors are likely to drive the market growth. Large number of individuals in North America have been affected by the increasing prevalence of numerous chronic ailments and infectious diseases. As per the Centers for Disease Control and Prevention (CDC), over 83% of children between 19-35 months are receiving vaccination for diphtheria, tetanus, and pertussis.

Get more details on this report - Request Free Sample PDF

The mass production of crucial medicines is likely to increase the use of bioreactors in the pharma industry. Since the past two decades, North America has demonstrated the development of thriving biopharmaceutical and biotechnology sectors. With ongoing research on gene therapy, monoclonal antibodies, and stem cells, bioreactor deployment has escalated considerably.

Impact of COVID-19 outbreak on North America bioreactors market outlook

The COVID-19 pandemic put a strain on healthcare systems throughout the world, necessitating the development of vaccines and monoclonal antibodies for the prevention and treatment of the deadly disease, as well as other autoimmune disorders. A significant amount of investment was set aside for studies in cell culture medium grown in bioreactors. As the global threat of infectious and chronic illnesses grows, the need for apt vaccinations and medications are likely to strengthen the industry outlook.

North America Market, By Product Type

The North America bioreactors market revenue from reusable segment will surpass USD 5.5 billion by 2028, owing to product features such as mass production, cost effectiveness, and easy storage of hot and fluid materials, reusable bioreactor sales. To address rising infectious disease concerns, pharmaceutical companies have increased their investment in research and new drug development. The increased need for vaccines and monoclonal antibodies will promote the adoption of reusable bioreactors in pharmaceutical manufacturing.

North America Market, By Molecule

The monoclonal antibodies (mAbs) segment will showcase around 12% growth rate during the forecast period, due to rising prevalence of various immune disorders and cancer in the region. In the recent past, colorectal, prostate, and lung cancer accounted for 43% of the total cancer cases diagnosed in men. mAbs are being widely used by the bio pharmaceutical and biotechnology companies to reduce the rising cancer burden.

North America Bioreactors Market, By End-use

The R&D organizations segment will gain remarkable momentum through 2028. Ongoing clinical trials, new product development, and introduction of new technologies such as gene therapy, cell line development, and stem cells, among others, has fostered the growth of R&D investments in the region. Continuous research expenditure by the regional governments to support the healthcare sector, and funding for new drug development will contribute to the industry forecast.

North America Market, By Country

U.S. bioreactors market size is expected to grow at a significant CAGR till 2028, attributed to the increasing usage of single-use bioreactors in biopharmaceutical sectors. According to the U.S. Government Accountability Office (GAO, 2017), key market participants invested around USD 89 billion on drug research, with the federal government funding USD 28 billion. The increasing frequency of infectious and chronic illnesses has increased demand for vaccinations.

Competitive Industry Landscape

Prominent participants operating across the market include Merck Group, Cytiva, Thermo Fischer, and Sartorius Stedim Biotech Group. To increase their revenues and attract new customers, companies are opting for various marketing strategies, including mergers and acquisitions, new product launch, partnerships, and collaborations, among others.